ArticleGlobal spine journal2026
Postoperative C-Reactive Protein Trajectories in Spine Surgery - Influence of Vancomycin Powder: A Secondary Analysis of a Prospective Randomized Controlled Trial.
Article in Global spine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Study DesignRandomized controlled trial.ObjectivesTo characterize postoperative C-reactive protein (CRP) trajectories as predictors of surgical site infection (SSI) following lumbar spine surgery, to determine optimal CRP thresholds, and to assess whether intrawound vancomycin powder affects postoperative CRP kinetics.MethodsData were drawn from a prospective randomized controlled trial enrolling 292 patients undergoing posterior lumbar interbody fusion. Patients received intrawound vancomycin powder (1 g) plus standard prophylaxis or standard prophylaxis alone. CRP was measured preoperatively and on days 1, 2, 3, 5, and 7. SSI was classified as overt (CDC criteria) or subclinical. ROC analysis evaluated prediction of any SSI at each time point.Results22 patients (7.5%) developed any SSI: 9 overt (3.1%) and 13 subclinical (4.5%). CRP peaked at day 5 in the overall cohort. SSI patients showed persistently elevated CRP through day 7, while uncomplicated patients declined after day 3. Day 7 CRP showed the highest discriminatory ability (AUC = 0.813; cutoff ≥79 mg/L; sensitivity 61.1%; specificity 91.4%; NPV 95.2%). Vancomycin did not alter CRP kinetics at any time point (all
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.